Europe Pharmaceutical Drug Delivery worth $703.19 billion by 2031
The report "Europe Pharmaceutical Drug Delivery Market by Route of Administration, [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application (Cancer, Diabetes), Care Setting (Hospital, Homecare)—Forecast to 2031” is projected to grow from USD 519.62 billion in 2026 and to reach USD 703.19 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period.
Browse 523 market data Tables and 60 Figures spread through 350 Pages and in-depth TOC on "Europe Pharmaceutical Drug Delivery Market by Route of Administration, [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application (Cancer, Diabetes), Care Setting (Hospital, Homecare)—Forecast to 2031”
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-pharmaceutical-drug-delivery-market-148622116.html
The Europe pharmaceutical drug delivery market is expanding due to increasing usage of biologics and biosimilars, rising prevalence of chronic illnesses, and a growing acceptance of emerging drug delivery devices such as auto-injectors, prefilled syringes, and inhalation drug delivery devices. Moreover, a high geriatric population, the preference for home care usage, and government support policies for patient-friendly drug delivery systems are fueling this market. Key trends in this market are self-administration, technology-driven drug delivery, sustainable drug delivery, and drug device combinations.
“By route of administration, injectable drug delivery is expected to be the largest segment during the forecast period.”
The injectable drug delivery segment is driven by Europe’s increasing reliance on biologics and biosimilars for the treatment of cancer, autoimmune, and chronic diseases. These prefilled injectables, available in syringe, auto-injector, or pen form, remain popular due to their ease of use, precision, and portability. Increasing acceptance of patient self-administration, coupled with support for combination product development, further validates injectables as the most popular administration route in Europe.
“By care setting, hospitals are expected to surpass other segments during the forecast period.”
The dominance of hospitals can be attributed to their high volume of acute care, infusion, and complex biologics that need monitoring. Hospitals in Europe benefit from a stronger purchasing position in their markets and a preference for adopting advanced infusion pumps, injectables, and controlled delivery systems early. Increasing surgical volumes, cancer cases, and emergency care also solidify that drug delivery remains in a hospital setting, despite the development of home healthcare options.
“Germany is expected to be the fastest-growing country in Europe during the forecast period.”
Germany’s rapid growth is subject to its well-functioning healthcare infrastructure, high proportion of biologic prescriptions, and increased adoption of user-controlled devices, such as auto-injectors and prefilled syringes. The country has a sizable number of seniors, an extensive hospital network, and favorable government policies that encourage the usage of superior delivery systems. Additionally, its long-standing strength in R&D and manufacturing in the pharmaceutical domain continues to promote the development of injectable, inhalation, and wearable delivery systems for various therapeutic classes.
Key Market Players
Key players operating in the Europe pharmaceutical drug delivery market are Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Fresenius Kabi (Germany), Becton, Dickinson and Company (US), Nemera (France), B. Braun (Germany), Gerresheimer AG (Germany), SHL Medical (Switzerland), Novo Nordisk (Denmark), Novartis (Switzerland), Sanofi (France), Baxter International (US), AstraZeneca (United Kingdom), Roche (Switzerland), and medmix (Switzerland).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Europe Pharmaceutical Drug Delivery Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
